Edwards secures FDA approval for tricuspid valve repair system

The US Food and Drug Administration (FDA) has approved Edwards Lifesciences’ tricuspid valve repair system, PASCAL Precision. The PASCAL Precision device is indicated to treat individuals with symptomatic severe tricuspid regurgitation. Edwards becomes the only provider to supply both repair and replacement options across the mitral and tricuspid valves. Credit: MAD.vertise / Shutterstock.com. The US Food and Drug Administration (FDA) has approved Edwards Lifesciences’ tricuspid valve repair system, PASCAL Precision. The transcatheter medical device is indicated to improve functional status and quality of life in patients experiencing symptomatic severe tricuspid regurgitation (TR) despite the administration of optimal medical therapy. Combine…

Source: Medical Device Network